Celgene Corporation, a biopharmaceutical company, discovers, develops, and commercializes therapies to treat cancer and immune-inflammatory related diseases in the United States and internationally. The companys commercial stage products include REVLIMID, an oral immunomodulatory drug for the treatment of multiple myeloma, myelodysplastic syndromes (MDS), and mantle cell lymphoma; VIDAZA, a pyrimidine nucleoside analog to treat intermediate-2 and high-risk MDS, and chronic myelomonocytic leukemia, as well as acute myeloid leukemia (AML); ABRAXANE, a solvent-free chemotherapy product for the treatment of breast, non-small cell lung, pancreatic, and gastric cancers; and POMALYST/IMNOVID for the treatment of multiple myeloma. Its commercial stage products also comprise THALOMID for the patients with multiple myeloma and for the acute treatment of the cutaneous manifestations of erythema nodosum leprosum; ISTODAX to treat cutaneous T-cell lymphoma; and FOCALIN, FOCALIN XR, and RITALIN LA products. The companys pre clinical and clinical stage products consist of OTEZLA for the treatment of psoriatic arthritis, psoriasis, and ankylosing spondylitis; CC-122 and CC-220 to treat hematological and solid tumor cancers; cellular therapies, such as PDA-001 and PDA-002 for Crohns and peripheral arterial diseases; CC-486, to treat MDS, AML, and solid tumors; Sotatercept and ACE-536 for the treatment of anemia in patients with rare blood disorders; CC-223 and CC-115 for lymphomas, hepatocellular, and prostate cancers; and CC-292 for the treatment of chronic lymphocytic leukemia and lymphomas. It has strategic drug discovery collaboration with Abide Therapeutics to enhance the treatment paradigm for patients with immune disorders. Celgene Corporation was founded in 1980 and is headquartered in Summit, New Jersey.
The Zacks Analyst Blog Highlights: Pharmacyclics, Celgene, Amgen and Regeneron - Press Releases27 Feb 2015, 7:30 amThe Zacks Analyst Blog Highlights: Pharmacyclics, Celgene, Amgen and Regeneron
Taking Stock26 Feb 2015, 5:21 pmRiding Higher All three major stock averages are competing for new headline highs. Both the broad-based S&P 500 and the Dow 30 closed at record highs within the past week. The financial media credited prospective Federal Reserve actions or, more accurately, lack of actions, when Chair Janet Yell... The post Taking Stock appeared first on Laguna Local News .
The single best stock to own today26 Feb 2015, 10:28 amAt The Motley Fool, we recommend a lot of different stocks, and for good reason. There's no one-size-fits-all formula for investing.
Biotech Stock Roundup: Pharmacyclics Up on Buyout Rumors, Celgene Drug Label Expanded - Analyst Blog26 Feb 2015, 9:07 amIs Pharmacyclics (PCYC) up for sale? J&J and Novartis are rumored to be interested in acquiring the company.
Celgene Gains on Label Expansion of Revlimid in the EU - Analyst Blog23 Feb 2015, 4:20 pmCelgene Corporation announced that Revlimid has received approval from the European Commission for the treatment of adults with previously untreated multiple myeloma who are not eligible for transplant.
Stock Market News for February 18, 2015 - Market News18 Feb 2015, 8:10 amBenchmarks started the holiday-shortened week on a positive note banking on encouraging news from Greece
Celgene Up on Abraxane Getting Positive Recommendation - Analyst Blog11 Feb 2015, 2:59 pmCelgene Corporation (CELG) was up 1.7% after the company announced that Abraxane has received a positive recommendation from the Scottish Medicines Consortium.
Biotech Stock Roundup: Achillion Impresses with HCV Data, Regeneron 4Q Results Top Estimates - Analyst Blog11 Feb 2015, 9:47 amThe hepatitis C virus (HCV) market remains in focus with Achillion (ACHN) presenting encouraging data.
Critical Alerts For Juno Therapeutics Inc, Westport Innovations, Disney, Twitter and Celgene Released By ...5 Feb 2015, 7:42 amCHICAGO, Feb. 5, 2015 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for JUNO, WPRT, DIS, TWTR and CELG. To see what our analysts have discovered about a particular stock, read the InvestorsObserver's PriceWatch Alert by selecting the corresponding link. (Note:...
The Zacks Analyst Blog Highlights: Amgen, Biogen, Celgene, AbbVie and Gilead - Press Releases5 Feb 2015, 7:30 amThe Zacks Analyst Blog Highlights: Amgen, Biogen, Celgene, AbbVie and Gilead